All In Biotech

Drug Trial Radar · NCT03615768

A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris

A Multi-center, Randomized, Single-blind, Paralelle, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Moderate Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Apr 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,617 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,617

Actual

Start

Aug 14, 2018

Primary completion

Feb 13, 2020

Study completion Apr 7, 2020

Sponsor

Lead sponsor
Lee's Pharmaceutical LimitedIndustry
Sponsor type
Industry
Collaborators
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
First posted
Aug 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to see if Adapalene-Clindamycin Combination Gel is effective and safe in the treatment of acne vulgaris, compared to adapalene gel alone and clindamycin gel alone. Adapalene and clindamycin have been reported to have a better effect in acne treatment when used together. This new formulation is also easier to use as it combines two products into a single gel and only needs to be used once a day.

Conditions

  • Acne Vulgaris

Interventions

  • Adapalene-Clindamycin Combination GelCombination product

    5mg Adapalene/50mg Clindamycin per 5g, applied nightly for 12 weeks

  • Adapalene GelDrug

    Differin 0.1% Gel, applied nightly for 12 weeks

  • Clindamycin GelDrug

    Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change From Baseline in Total Lesion CountsTime frame: Week 12
  2. Proportion of patients who has at least a two-point reduction in Investigator Global Assessment (IGA) compared to baselineTime frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Dermatology and Hospital for Skin Diseases, Chinese Academy of Medical Sciences

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.